Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
IQVIA Holdings Inc. senior vice president of FP&A Michael J. Fedock reported a disposition of common stock. On 01/28/2026, he disposed of 381 shares of IQVIA common stock at a reported price of $239.76 per share, leaving him with 5,391 shares held directly after the transaction.
IQVIA Holdings executive Bernd Haas, EVP of AI and Technology Solutions, reported his initial holdings of the company’s equity. He directly beneficially owns 16,589 shares of IQVIA common stock, which include restricted stock units that are scheduled to vest on February 13, 2026 and January 28, 2028. He also holds multiple stock appreciation rights over IQVIA common stock, with grants covering share amounts such as 2,781, 4,032 and 8,778, and exercise prices ranging from $95.23 to $250.43, expiring between 2028 and 2035. Several of these awards have portions already vested, with the remaining parts set to vest in annual installments beginning in 2026.
IQVIA Holdings executive Alistair Grenfell, President, Commercial Solutions, reported his initial ownership in the company as of 12/31/2025. He beneficially owns 17,874 shares of common stock held directly. In addition, he holds several stock appreciation rights (SARs) over IQVIA common stock, including 8,193 shares at $250.43 per share exercisable until 02/10/2032 and 10,300 shares at $232.11 per share expiring on 02/13/2033, with portions already vested and the remainder scheduled to vest beginning in 2026. Further SAR grants cover 17,266 shares at $214.34 expiring 02/07/2034 and 28,091 shares at $203.43 expiring 01/28/2035, with vesting in annual installments starting in 2026.
IQVIA Holdings Inc. insider files initial ownership report. Senior Vice President of FP&A Michael J. Fedock reported beneficial ownership of 5,772 shares of IQVIA common stock, held directly. This amount includes restricted stock units that were granted between February 2023 and January 2025 and are scheduled to vest in annual installments beginning in 2026.
Fedock also reported several stock appreciation rights, each deliverable in IQVIA common stock, with exercise prices between $183.82 and $250.43 per share and expiration dates ranging from February 2031 to January 2035. Portions of these awards are already vested, with the remaining amounts scheduled to vest in annual installments starting in 2026.
IQVIA Holdings Inc. executive James G. Berkshire, EVP, Global Infrastructure and Operations, has filed an initial ownership report. He reports beneficial ownership of 6,735 shares of IQVIA common stock, held directly.
He also holds multiple stock appreciation rights covering IQVIA common stock, with exercise prices ranging from $131.82 to $250.43 per share and expiration dates extending through 2035. Footnotes state that portions of certain grants are already vested and that additional portions are scheduled to vest on February 13, 2026, in two annual installments beginning on February 7, 2026, and in three annual installments beginning on January 28, 2026.
IQVIA Holdings insider activity: A senior executive reported several stock transactions in IQVIA Holdings Inc. common stock on 12/18/2025. The filing shows an exercise of 50,000 stock appreciation rights at an exercise price of $59.90 per share, resulting in the acquisition of 50,000 shares of common stock.
On the same date, the executive sold 36,564 shares of common stock in open-market transactions at a weighted average price of $222.43 per share, and a further 13,436 shares at $222.91 per share. Following these transactions, the executive directly owned 807,163 shares of IQVIA common stock and indirectly owned 543,302 shares through the Orohena Trust.
A planned Rule 144 sale has been filed for IQV common stock. The notice covers 36564 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of 8132875.67, while 170300000 shares are outstanding. The approximate sale date listed is 12/18/2025 on the NYSE.
The filing also discloses that Ari Bousbib sold 56557 common shares of the same issuer on 10/29/2025, generating gross proceeds of 12460983.24. These details show both the upcoming planned transaction and recent sales over the prior three months, as required under Rule 144 disclosure rules.
IQVIA Holdings Inc. reported that it entered into an amendment to its Fifth Amended and Restated Credit Agreement. The amendment refinances existing Term A-1 and Term A-2 dollar term loans into a new class of term A dollar loans, and refinances existing term A euro loans into a new class of term A euro loans. It also consolidates all current U.S., Japanese, and Swiss/Multicurrency revolving credit commitments into a new class of revolving credit commitments.
The amendment reduces the interest rate on term A loans and revolving credit loans denominated in U.S. dollars by eliminating the term SOFR credit spread adjustment. In addition, the Swiss Subsidiary Borrower and the Japanese Borrower are released from all obligations as borrowers under the credit agreement.
IQVIA Holdings Inc. (IQV): A newly appointed director, William G. Kaelin, Jr., filed a Form 3 initial statement of beneficial ownership. The filing indicates no securities are beneficially owned as of the event date 11/05/2025. The relationship is listed as Director, and the form was filed by one reporting person. The submission was signed by an attorney-in-fact.
IQVIA (IQV) director Leslie Wims Morris reported acquiring 146 deferred share units on 11/05/2025, coded as an award (A), at a disclosed derivative price of $210.12. Following the transaction, she beneficially owns 4,735 deferred share units, held directly.
Each deferred share converts into one share of common stock upon settlement. Per the plan, settlement occurs when the director service ends, upon a change in control, or upon death; there is no expiration date.